These are the most deadly pathogens — so why aren’t drug companies targeting them?
Despite calls to step up efforts, investment in antimicrobial resistance is still insufficient.
Despite calls to step up efforts, investment in antimicrobial resistance is still insufficient.
What's Your Reaction?
Tomas Kauer - Moderator
www.tomaskauer.com
